

# Paolo Martelletti

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/5533259/paolo-martelletti-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

258  
papers

6,043  
citations

41  
h-index

62  
g-index

316  
ext. papers

7,791  
ext. citations

5.9  
avg, IF

6.55  
L-index

#	Paper	IF	Citations
258	Cost of healthcare for patients with migraine in five European countries: results from the International Burden of Migraine Study (IBMS). <i>Journal of Headache and Pain</i> , <b>2012</b> , 13, 361-78	8.8	198
257	European headache federation guideline on the use of monoclonal antibodies acting on the calcitonin gene related peptide or its receptor for migraine prevention. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 6	8.8	158
256	Neuromodulation of chronic headaches: position statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , <b>2013</b> , 14, 86	8.8	141
255	Noninvasive vagus nerve stimulation as acute therapy for migraine: The randomized PRESTO study. <i>Neurology</i> , <b>2018</b> , 91, e364-e373	6.5	130
254	Air Pollution and the Novel Covid-19 Disease: a Putative Disease Risk Factor. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-5	2.7	126
253	Psychiatric comorbidity in patients with chronic daily headache and migraine: a selective overview including personality traits and suicide risk. <i>Journal of Headache and Pain</i> , <b>2009</b> , 10, 283-90	8.8	109
252	Aids to management of headache disorders in primary care (2nd edition) : on behalf of the European Headache Federation and Lifting The Burden: the Global Campaign against Headache. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 57	8.8	98
251	A two years open-label prospective study of OnabotulinumtoxinA 195 U in medication overuse headache: a real-world experience. <i>Journal of Headache and Pain</i> , <b>2015</b> , 17, 1	8.8	93
250	Hormonal contraceptives and risk of ischemic stroke in women with migraine: a consensus statement from the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESC). <i>Journal of Headache and Pain</i> , <b>2017</b> , 18, 108	8.8	91
249	Underdiagnosis and undertreatment of migraine in Italy: a survey of patients attending for the first time 10 headache centres. <i>Cephalalgia</i> , <b>2009</b> , 29, 1285-93	6.1	82
248	Gut-brain Axis and migraine headache: a comprehensive review. <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 15	8.8	80
247	Journal Citation Reports 2013 tells headache experts that competitive environment has changed. <i>Journal of Headache and Pain</i> , <b>2014</b> , 15,	8.8	78
246	Addendum: Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , <b>2018</b> , 9,	4.1	78
245	My Migraine Voice survey: a global study of disease burden among individuals with migraine for whom preventive treatments have failed. <i>Journal of Headache and Pain</i> , <b>2018</b> , 19, 115	8.8	76
244	Chronic migraine: comorbidities, risk factors, and rehabilitation. <i>Internal and Emergency Medicine</i> , <b>2010</b> , 5 Suppl 1, S13-9	3.7	75
243	Refractory chronic migraine: a consensus statement on clinical definition from the European Headache Federation. <i>Journal of Headache and Pain</i> , <b>2014</b> , 15, 47	8.8	72
242	Refractory chronic cluster headache: a consensus statement on clinical definition from the European Headache Federation. <i>Journal of Headache and Pain</i> , <b>2014</b> , 15, 79	8.8	69

241	Chronic migraine plus medication overuse headache: two entities or not?. <i>Journal of Headache and Pain</i> , <b>2011</b> , 12, 593-601	8.8	68
240	European Headache Federation consensus on technical investigation for primary headache disorders. <i>Journal of Headache and Pain</i> , <b>2015</b> , 17, 5	8.8	66
239	Current and emerging evidence-based treatment options in chronic migraine: a narrative review. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 92	8.8	65
238	'Ictal epileptic headache': recent concepts for new classifications criteria. <i>Cephalalgia</i> , <b>2012</b> , 32, 723-4	6.1	64
237	Guideline on the use of onabotulinumtoxinA in chronic migraine: a consensus statement from the European Headache Federation. <i>Journal of Headache and Pain</i> , <b>2018</b> , 19, 91	8.8	64
236	Gepants for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , <b>2019</b> , 28, 555-567	5.9	62
235	Psychiatric comorbidity and suicide risk in patients with chronic migraine. <i>Neuropsychiatric Disease and Treatment</i> , <b>2010</b> , 6, 81-91	3.1	62
234	A six year retrospective review of occipital nerve stimulation practice--controversies and challenges of an emerging technique for treating refractory headache syndromes. <i>Journal of Headache and Pain</i> , <b>2013</b> , 14, 67	8.8	60
233	CGRP receptor antagonists: an expanding drug class for acute migraine?. <i>Expert Opinion on Investigational Drugs</i> , <b>2012</b> , 21, 807-18	5.9	53
232	Serotonin receptor agonists in the acute treatment of migraine: a review on their therapeutic potential. <i>Journal of Pain Research</i> , <b>2018</b> , 11, 515-526	2.9	51
231	Emerging treatment for chronic migraine and refractory chronic migraine. <i>Expert Opinion on Emerging Drugs</i> , <b>2012</b> , 17, 393-406	3.7	51
230	Impact of migraine on fibromyalgia symptoms. <i>Journal of Headache and Pain</i> , <b>2015</b> , 17, 28	8.8	51
229	Developing a core outcome domain set to assessing effectiveness of interdisciplinary multimodal pain therapy: the VAPAIN consensus statement on core outcome domains. <i>Pain</i> , <b>2018</b> , 159, 673-683	8	50
228	OnabotulinumtoxinA 155 U in medication overuse headache: a two years prospective study. <i>SpringerPlus</i> , <b>2015</b> , 4, 826		50
227	CGRP and migraine from a cardiovascular point of view: what do we expect from blocking CGRP?. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 27	8.8	47
226	European headache federation consensus on the definition of resistant and refractory migraine : Developed with the endorsement of the European Migraine & Headache Alliance (EMHA). <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 76	8.8	47
225	New insights into the cardiovascular risk of migraine and the role of white matter hyperintensities: is gold all that glitters?. <i>Journal of Headache and Pain</i> , <b>2013</b> , 14, 9	8.8	46
224	Tumor necrosis factor gene polymorphism in migraine. <i>Headache</i> , <b>2002</b> , 42, 341-5	4.2	46

223	New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 97-98	19.7	45
222	Improving care through health economics analyses: cost of illness and headache. <i>Journal of Headache and Pain</i> , <b>2008</b> , 9, 199-206	8.8	43
221	A double-blind, randomized, multicenter, Italian study of frovatriptan versus almotriptan for the acute treatment of migraine. <i>Journal of Headache and Pain</i> , <b>2011</b> , 12, 361-8	8.8	41
220	Association of diet and headache. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 106	8.8	41
219	Altered kynurenine pathway metabolites in serum of chronic migraine patients. <i>Journal of Headache and Pain</i> , <b>2015</b> , 17, 47	8.8	39
218	An open-label prospective study of the real-life use of onabotulinumtoxinA for the treatment of chronic migraine: the REPOSE study. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 26	8.8	38
217	Ictal epileptic headache: an old story with courses and appeals. <i>Journal of Headache and Pain</i> , <b>2012</b> , 13, 607-13	8.8	38
216	Salivary cortisol, dehydroepiandrosterone-sulphate (DHEA-S) and testosterone in women with chronic migraine. <i>Journal of Headache and Pain</i> , <b>2006</b> , 7, 90-4	8.8	38
215	Cervicogenic headache: practical approaches to therapy. <i>CNS Drugs</i> , <b>2004</b> , 18, 793-805	6.7	38
214	Cervical 10 kHz spinal cord stimulation in the management of chronic, medically refractory migraine: A prospective, open-label, exploratory study. <i>European Journal of Pain</i> , <b>2016</b> , 20, 70-8	3.7	38
213	Anti-CGRP monoclonal antibodies in migraine: current perspectives. <i>Internal and Emergency Medicine</i> , <b>2016</b> , 11, 1045-1057	3.7	37
212	Impact of COVID-19 prevention measures on risk of health care-associated Clostridium difficile infection. <i>American Journal of Infection Control</i> , <b>2021</b> , 49, 640-642	3.8	36
211	Inhibition of intercellular adhesion molecule-1 (ICAM-1), soluble ICAM-1 and interleukin-4 by nitric oxide expression in migraine patients. <i>Journal of Molecular Medicine</i> , <b>1997</b> , 75, 448-53	5.5	34
210	Emerging drugs for migraine treatment: an update. <i>Expert Opinion on Emerging Drugs</i> , <b>2018</b> , 23, 301-318	3.7	34
209	Effect of exogenous estrogens and progestogens on the course of migraine during reproductive age: a consensus statement by the European Headache Federation (EHF) and the European Society of Contraception and Reproductive Health (ESCRH). <i>Journal of Headache and Pain</i> , <b>2018</b> , 19, 76	8.8	34
208	Calcitonin gene-related peptide receptor as a novel target for the management of people with episodic migraine: current evidence and safety profile of erenumab. <i>Journal of Pain Research</i> , <b>2017</b> , 10, 2751-2760	2.9	33
207	Long-term Treatment Benefits and Prolonged Efficacy of OnabotulinumtoxinA in Patients Affected by Chronic Migraine and Medication Overuse Headache over 3 Years of Therapy. <i>Frontiers in Neurology</i> , <b>2017</b> , 8, 586	4.1	33
206	Genetics of migraine and pharmacogenomics: some considerations. <i>Journal of Headache and Pain</i> , <b>2007</b> , 8, 334-9	8.8	33

205	Diagnosis and management of migraine in ten steps. <i>Nature Reviews Neurology</i> , <b>2021</b> , 17, 501-514	15	33
204	Altered serum levels of kynurenine metabolites in patients affected by cluster headache. <i>Journal of Headache and Pain</i> , <b>2015</b> , 17, 27	8.8	32
203	Emerging drugs for migraine treatment. <i>Expert Opinion on Emerging Drugs</i> , <b>2015</b> , 20, 137-47	3.7	31
202	Genetic polymorphisms related to efficacy and overuse of triptans in chronic migraine. <i>Journal of Headache and Pain</i> , <b>2010</b> , 11, 431-5	8.8	30
201	Long-term benefits of botulinum toxin type A (BOTOX) in chronic daily headache: a five-year long experience. <i>Journal of Headache and Pain</i> , <b>2006</b> , 7, 407-12	8.8	30
200	Lasmiditan for the treatment of migraine. <i>Expert Opinion on Investigational Drugs</i> , <b>2017</b> , 26, 227-234	5.9	29
199	Incidence and determinants of high-sensitivity troponin and natriuretic peptides elevation at admission in hospitalized COVID-19 pneumonia patients. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 1467-1476 <sup>28</sup>	3.7	28
198	COVID-19: is it just a lung disease? A case-based review. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-6	2.7	28
197	Cost of chronic and episodic migraine patients in continuous treatment for two years in a tertiary level headache Centre. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 120	8.8	28
196	Optimising migraine treatment: from drug-drug interactions to personalized medicine. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 56	8.8	27
195	Choosing the safest acute therapy during chronic migraine prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 399-406	5.5	27
194	Targeting CGRP for migraine treatment: mechanisms, antibodies, small molecules, perspectives. <i>Expert Review of Neurotherapeutics</i> , <b>2020</b> , 20, 627-641	4.3	27
193	Reduction of Multidrug-Resistant (MDR) Bacterial Infections during the COVID-19 Pandemic: A Retrospective Study. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	26
192	Clinical Management of Adult Coronavirus Infection Disease 2019 (COVID-19) Positive in the Setting of Low and Medium Intensity of Care: a Short Practical Review. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-6	2.7	25
191	Frequencies of genetic polymorphisms related to triptans metabolism in chronic migraine. <i>Journal of Headache and Pain</i> , <b>2010</b> , 11, 151-6	8.8	25
190	Prevalence and burden of primary headache in Akaki textile mill workers, Ethiopia. <i>Journal of Headache and Pain</i> , <b>2008</b> , 9, 119-28	8.8	25
189	Mental turmoil, suicide risk, illness perception, and temperament, and their impact on quality of life in chronic daily headache. <i>Journal of Headache and Pain</i> , <b>2008</b> , 9, 349-57	8.8	25
188	Correlation between Migraine Severity and Cholesterol Levels. <i>Pain Practice</i> , <b>2015</b> , 15, 662-70	3	24

187	Migraine and sleep disorders: a systematic review. <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 126	8.8	24
186	Use of Nonsteroidal Anti-Inflammatory Drugs for Symptomatic Treatment of Episodic Headache. <i>Pain Practice</i> , <b>2017</b> , 17, 392-401	3	23
185	Improving quality in population surveys of headache prevalence, burden and cost: key methodological considerations. <i>Journal of Headache and Pain</i> , <b>2013</b> , 14, 87	8.8	23
184	Onabotulinumtoxin A for the management of chronic migraine in current clinical practice: results of a survey of sixty-three Italian headache centers. <i>Journal of Headache and Pain</i> , <b>2017</b> , 18, 66	8.8	23
183	Consistent effects of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: additional findings from the randomized, sham-controlled, double-blind PRESTO trial. <i>Journal of Headache and Pain</i> , <b>2018</b> , 19, 101	8.8	23
182	Modulation of nitric oxide synthase by nitric oxide donor compounds in migraine. <i>International Journal of Clinical and Laboratory Research</i> , <b>1998</b> , 28, 135-9		22
181	Efficacy of dosing and re-dosing of two oral fixed combinations of indomethacin, prochlorperazine and caffeine compared with oral sumatriptan in the acute treatment of multiple migraine attacks: a double-blind, double-dummy, randomised, parallel group, multicentre study. <i>International Journal of Clinical Practice</i> , <b>2007</b> , 61, 1256-69	2.9	22
180	Chromosome 6p-encoded HLA-DR2 determination discriminates migraine without aura from migraine with aura. <i>Human Immunology</i> , <b>1999</b> , 60, 69-74	2.3	22
179	"Capsaicin-sensitive" sensory neurons in cluster headache: pathophysiological aspects and therapeutic indication. <i>Headache</i> , <b>1994</b> , 34, 132-7	4.2	21
178	Chronic migraine: current concepts and ongoing treatments. <i>European Review for Medical and Pharmacological Sciences</i> , <b>2011</b> , 15, 1401-20	2.9	21
177	Chronic migraine treatment: from OnabotulinumtoxinA onwards. <i>Expert Review of Neurotherapeutics</i> , <b>2016</b> , 16, 1217-27	4.3	20
176	Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study. <i>Journal of Headache and Pain</i> , <b>2012</b> , 13, 401-6	8.8	20
175	Putative neuroimmunological mechanisms in cluster headache. An integrated hypothesis. <i>Headache</i> , <b>1996</b> , 36, 312-5	4.2	20
174	Extremely Severe Case of COVID-19 Pneumonia Recovered Despite Bad Prognostic Indicators: a Didactic Report. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-4	2.7	20
173	Sumatriptan succinate : pharmacokinetics of different formulations in clinical practice. <i>Expert Opinion on Pharmacotherapy</i> , <b>2012</b> , 13, 2369-80	4	19
172	Future drugs for migraine. <i>Internal and Emergency Medicine</i> , <b>2009</b> , 4, 367-73	3.7	19
171	The Global Campaign (GC) to Reduce the Burden of Headache Worldwide. The International Team for Specialist Education (ITSE). <i>Journal of Headache and Pain</i> , <b>2005</b> , 6, 261-3	8.8	19
170	Headache service quality: evaluation of quality indicators in 14 specialist-care centres. <i>Journal of Headache and Pain</i> , <b>2016</b> , 17, 111	8.8	19

169	Recurrent COVID-19 pneumonia in the course of chemotherapy: Consequence of a weakened immune system?. <i>Journal of Medical Virology</i> , <b>2021</b> , 93, 1882-1884	19.7	19
168	Hyperbaric oxygen in chronic cluster headaches: influence on serotonergic pathways. <i>Undersea and Hyperbaric Medicine</i> , <b>1997</b> , 24, 117-22	0.9	19
167	Proinflammatory pathways in cervicogenic headache. <i>Clinical and Experimental Rheumatology</i> , <b>2000</b> , 18, S33-8	2.2	19
166	Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. <i>Expert Review of Neurotherapeutics</i> , <b>2018</b> , 18, 167-176	4.3	18
165	Persistent post-traumatic headache: a migrainous loop or not? The clinical evidence. <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 55	8.8	18
164	Patient selection for migraine preventive treatment with anti-CGRP(r) monoclonal antibodies. <i>Expert Review of Neurotherapeutics</i> , <b>2019</b> , 19, 769-776	4.3	17
163	Fathoming the kynurenine pathway in migraine: why understanding the enzymatic cascades is still critically important. <i>Internal and Emergency Medicine</i> , <b>2015</b> , 10, 413-21	3.7	17
162	The Application of CGRP(r) Monoclonal Antibodies in Migraine Spectrum: Needs and Priorities. <i>BioDrugs</i> , <b>2017</b> , 31, 483-485	7.9	17
161	Ubrogepant for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 755-759	4	16
160	Persistent Post-Traumatic Headache and Migraine: Pre-Clinical Comparisons. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	16
159	Sodium channel antagonists for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2014</b> , 15, 1697-706	4	16
158	Overattachment and perceived disability in chronic migraineurs. <i>Clinical Neurology and Neurosurgery</i> , <b>2013</b> , 115, 954-8	2	16
157	Clinical factors associated with death in 3044 COVID-19 patients managed in internal medicine wards in Italy: results from the SIMI-COVID-19 study of the Italian Society of Internal Medicine (SIMI). <i>Internal and Emergency Medicine</i> , <b>2021</b> , 16, 1005-1015	3.7	16
156	Shaping the future of migraine targeting Calcitonin-Gen-Related-Peptide with the Disease-Modifying Migraine Drugs (DMMDs). <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 60	8.8	15
155	Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. <i>Therapeutic Advances in Neurological Disorders</i> , <b>2016</b> , 9, 414-23	6.6	15
154	The omics in migraine. <i>Journal of Headache and Pain</i> , <b>2013</b> , 14, 55	8.8	15
153	Psychometric properties of the stagnation scale in medication overuse headache patients. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, 1052	8.8	15
152	Treatment of perimenstrual migraine with triptans: an update. <i>Current Pain and Headache Reports</i> , <b>2012</b> , 16, 445-51	4.2	15

151	The validation of the Italian Perceived Disability Scale (IPDS) in chronic daily headache sufferers. <i>Journal of Headache and Pain</i> , <b>2009</b> , 10, 21-6	8.8	15
150	Gene polymorphisms involved in triptans pharmacokinetics and pharmacodynamics in migraine therapy. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 39-47	5.5	15
149	Progressive Deactivation of 5HT Receptors on Mononuclear Cells during Migraine Crisis. <i>Cephalalgia</i> , <b>1989</b> , 9, 93-94	6.1	15
148	Acute headache management in emergency department. A narrative review. <i>Internal and Emergency Medicine</i> , <b>2020</b> , 15, 109-117	3.7	15
147	Profiling lasmiditan as a treatment option for migraine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2020</b> , 21, 147-153	4	15
146	Coinfection of Tuberculosis Pneumonia and COVID-19 in a Patient Vaccinated with Bacille Calmette-Guérin (BCG): Case Report. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-4	2.7	15
145	Comorbidities of primary headache disorders: a literature review with meta-analysis. <i>Journal of Headache and Pain</i> , <b>2021</b> , 22, 71	8.8	15
144	Pharmacokinetic evaluation of frovatriptan. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2011</b> , 7, 1449-58	5.5	14
143	Aspirin and tension-type headache. <i>Journal of Headache and Pain</i> , <b>2007</b> , 8, 49-55	8.8	14
142	Advances in orally administered pharmacotherapy for the treatment of migraine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2019</b> , 20, 209-218	4	14
141	Epidural corticosteroid blockade in cervicogenic headache. <i>European Review for Medical and Pharmacological Sciences</i> , <b>1998</b> , 2, 31-6	2.9	14
140	Proinflammatory cytokines in cervicogenic headache. <i>Functional Neurology</i> , <b>1999</b> , 14, 159-62	2.2	14
139	Migraine, low-dose combined hormonal contraceptives, and ischemic stroke in young women: a systematic review and suggestions for future research. <i>Expert Review of Neurotherapeutics</i> , <b>2020</b> , 20, 313-317	4.3	13
138	Real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. <i>Journal of Headache and Pain</i> , <b>2017</b> , 18, 93	8.8	13
137	A Critical Evaluation on MOH Current Treatments. <i>Current Treatment Options in Neurology</i> , <b>2017</b> , 19, 32	4.4	13
136	White matter hyperintensities and self-reported depression in a sample of patients with chronic headache. <i>Journal of Headache and Pain</i> , <b>2012</b> , 13, 661-7	8.8	13
135	Proinflammatory mediators and migraine pathogenesis: moving towards CGRP as a target for a novel therapeutic class. <i>Expert Review of Neurotherapeutics</i> , <b>2008</b> , 8, 1347-54	4.3	13
134	Evidence for an immune-mediated mechanism in food-induced migraine from a study on activated T-cells, IgG4 subclass, anti-IgG antibodies and circulating immune complexes. <i>Headache</i> , <b>1989</b> , 29, 664-70	4.2	13



133	Global Burden of Headache Disorders in Children and Adolescents 2007-2017. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 18,	4.6	13
132	Long-COVID Headache. <i>SN Comprehensive Clinical Medicine</i> , <b>2021</b> , 3, 1-3	2.7	13
131	Fremanezumab for the preventive treatment of migraine in adults. <i>Expert Review of Clinical Pharmacology</i> , <b>2019</b> , 12, 741-748	3.8	12
130	Acute sleep deprivation enhances susceptibility to the migraine substrate cortical spreading depolarization. <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 86	8.8	12
129	Headache: Cluster headache treatment - RCTs versus real-world evidence. <i>Nature Reviews Neurology</i> , <b>2016</b> , 12, 557-8	15	12
128	Pharmacogenetic insights into migraine treatment in children. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 1539-50	2.6	12
127	Acute migraine in the Emergency Department: extending European principles of management. <i>Internal and Emergency Medicine</i> , <b>2008</b> , 3 Suppl 1, S17-24	3.7	12
126	Practical and clinical utility of non-invasive vagus nerve stimulation (nVNS) for the acute treatment of migraine: a post hoc analysis of the randomized, sham-controlled, double-blind PRESTO trial. <i>Journal of Headache and Pain</i> , <b>2018</b> , 19, 98	8.8	12
125	Migraine and cluster headache show impaired neurosteroids patterns. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 61	8.8	11
124	Update on Medication-Overuse Headache and Its Treatment. <i>Current Treatment Options in Neurology</i> , <b>2015</b> , 17, 368	4.4	11
123	Latest clinical recommendations on valproate use for migraine prophylaxis in women of childbearing age: overview from European Medicines Agency and European Headache Federation. <i>Journal of Headache and Pain</i> , <b>2018</b> , 19, 68	8.8	11
122	Erenumab is effective in reducing migraine frequency and improving physical functioning. <i>BMJ Evidence-Based Medicine</i> , <b>2019</b> , 24, 76	2.7	11
121	Rehabilitating chronic migraine complicated by medication overuse headaches: how can we prevent migraine relapse?. <i>Internal and Emergency Medicine</i> , <b>2011</b> , 6, 23-8	3.7	11
120	Patient outcome in migraine prophylaxis: the role of psychopharmacological agents. <i>Patient Related Outcome Measures</i> , <b>2010</b> , 1, 107-18	2.9	11
119	Structural and Functional Brain Changes in Migraine. <i>Pain and Therapy</i> , <b>2021</b> , 10, 211-223	3.6	11
118	Rapid referral for headache management from emergency department to headache centre: four years data. <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 25	8.8	10
117	Pharmacokinetics and safety of a new aspirin formulation for the acute treatment of primary headaches. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2014</b> , 10, 1381-95	5.5	10
116	Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 1043-50	5.5	10

115	The Relation between Persistent Post-Traumatic Headache and PTSD: Similarities and Possible Differences. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	9
114	Novel synthetic treatment options for migraine. <i>Expert Opinion on Pharmacotherapy</i> , <b>2021</b> , 22, 907-922	4	9
113	Position Paper on Post-Traumatic Headache: The Relationship Between Head Trauma, Stress Disorder, and Migraine. <i>Pain and Therapy</i> , <b>2021</b> , 10, 1-13	3.6	9
112	Evaluating and managing severe headache in the emergency department. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 277-285	4.3	9
111	Non-Pharmacological Approaches to Headaches: Non-Invasive Neuromodulation, Nutraceuticals, and Behavioral Approaches. <i>International Journal of Environmental Research and Public Health</i> , <b>2021</b> , 18,	4.6	9
110	Pharmacogenetic considerations for migraine therapies. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2018</b> , 14, 1161-1167	5.5	9
109	Aids for management of common headache disorders in primary care. <i>Journal of Headache and Pain</i> , <b>2007</b> , 8 Suppl 1, S2	8.8	9
108	Headache as a Prognostic Factor for COVID-19. Time to Re-evaluate. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 1-2	2.7	8
107	Direct and indirect costs of cluster headache: a prospective analysis in a tertiary level headache centre. <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 44	8.8	8
106	Inflammatory mechanisms in cervicogenic headache: an integrative view. <i>Current Pain and Headache Reports</i> , <b>2002</b> , 6, 315-9	4.2	8
105	Atogepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Preventive treatment of migraine. <i>Drugs of the Future</i> , <b>2020</b> , 45, 285	2.3	8
104	CGRP Receptor Antagonists and 5-HT <sub>1F</sub> Receptor Agonist in the Treatment of Migraine. <i>Journal of Clinical Medicine</i> , <b>2021</b> , 10,	5.1	8
103	Burden and attitude to resistant and refractory migraine: a survey from the European Headache Federation with the endorsement of the European Migraine & Headache Alliance. <i>Journal of Headache and Pain</i> , <b>2021</b> , 22, 39	8.8	8
102	Tailoring Treatment in Polymorbid Migraine Patients through Personalized Medicine. <i>CNS Drugs</i> , <b>2018</b> , 32, 559-565	6.7	8
101	Job Satisfaction Mediates the Association between Perceived Disability and Work Productivity in Migraine Headache Patients. <i>International Journal of Environmental Research and Public Health</i> , <b>2019</b> , 16,	4.6	7
100	Lack of association between oxidative stress-related gene polymorphisms and chronic migraine in an Italian population. <i>Expert Review of Neurotherapeutics</i> , <b>2015</b> , 15, 215-25	4.3	7
99	Treatment of menstrual migraine: utility of control of related mood disturbances. <i>Expert Review of Neurotherapeutics</i> , <b>2014</b> , 14, 493-502	4.3	7
98	Headache and mood disorders. <i>Journal of Headache and Pain</i> , <b>2005</b> , 6, 250-3	8.8	7

97	In vitro interactions of serotonin (5-HT) with mononuclear cells from migraine patients: alterations related to the phase of the attack. <i>Journal of Neuroimmunology</i> , <b>1988</b> , 18, 17-24	3.5	7
96	Fremanezumab for the prevention of chronic and episodic migraine. <i>Drugs of Today</i> , <b>2019</b> , 55, 265-276	2.5	7
95	The clinical and public health implications and risks of widening the definition of chronic migraine. <i>Cephalalgia</i> , <b>2020</b> , 40, 407-410	6.1	7
94	Pharmacokinetic evaluation of almotriptan for the treatment of migraines. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2013</b> , 9, 637-44	5.5	6
93	Role of NSAIDs in acute treatment of headache. <i>Drug Development Research</i> , <b>2007</b> , 68, 276-281	5.1	6
92	Mapping Assessments Instruments for Headache Disorders against the ICF Biopsychosocial Model of Health and Disability. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 18,	4.6	6
91	Depression and insomnia are independently associated with satisfaction and enjoyment of life in medication-overuse headache patients. <i>International Journal of Psychiatry in Medicine</i> , <b>2016</b> , 51, 442-455 <sup>1</sup>		6
90	Failure of long-term results of epidural steroid injection in cervicogenic headache. <i>European Review for Medical and Pharmacological Sciences</i> , <b>1998</b> , 2, 10	2.9	6
89	Acute treatment of migraine: quo vadis?. <i>Expert Opinion on Pharmacotherapy</i> , <b>2017</b> , 18, 1035-1037	4	5
88	The future of pharmacogenetics in the treatment of migraine. <i>Pharmacogenomics</i> , <b>2019</b> , 20, 1159-1173	2.6	5
87	Deciphering the task of N-acetyl aspartate in migraine. <i>Expert Review of Neurotherapeutics</i> , <b>2012</b> , 12, 1057-9	4.3	5
86	Headache medicine: academic teaching in Europe. The Sapienza University Master's Degree. <i>Headache</i> , <b>2007</b> , 47, 1224-5; author reply 1225-7	4.2	5
85	What is changing in chronic migraine treatment? An algorithm for onabotulinumtoxinA treatment by the Italian chronic migraine group. <i>Expert Review of Neurotherapeutics</i> , <b>2020</b> , 20, 1275-1286	4.3	5
84	Acute, transitional and long-term cluster headache treatment: pharmacokinetic issues. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2016</b> , 12, 1011-20	5.5	5
83	Using INTERCheck to Evaluate the Incidence of Adverse Events and Drug-Drug Interactions in Out- and Inpatients Exposed to Polypharmacy. <i>Drugs - Real World Outcomes</i> , <b>2020</b> , 7, 243-249	2.2	4
82	Nitric oxide: emerging implications for headache mechanics. <i>Journal of Headache and Pain</i> , <b>2001</b> , 2, 67-73.8		4
81	Upregulated expression of peripheral serotonergic receptors in migraine and cluster headache by sumatriptan. <i>International Journal of Clinical Pharmacology Research</i> , <b>1994</b> , 14, 165-75		4
80	Rimegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. <i>Drugs of the Future</i> , <b>2019</b> , 44, 635	2.3	4

79	Persistent post-traumatic headache: a migrainous loop or not? The preclinical evidence. <i>Journal of Headache and Pain</i> , <b>2020</b> , 21, 90	8.8	4
78	Early Management of OnabotulinumtoxinA Treatment in Chronic Migraine: Insights from a Real-Life European Multicenter Study. <i>Pain and Therapy</i> , <b>2021</b> , 10, 637-650	3.6	4
77	Medication overuse and drug addiction: a narrative review from addiction perspective. <i>Journal of Headache and Pain</i> , <b>2021</b> , 22, 32	8.8	4
76	Recent advancements in tension-type headache: a narrative review. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 793-803	4.3	4
75	Development and validation of the ID-EC - the ITALIAN version of the identify chronic migraine. <i>Journal of Headache and Pain</i> , <b>2019</b> , 20, 15	8.8	4
74	Healthcare resource use and indirect costs associated with migraine in Italy: results from the survey. <i>Journal of Medical Economics</i> , <b>2021</b> , 24, 717-726	2.4	4
73	Headache onset after vaccination against SARS-CoV-2: a systematic literature review and meta-analysis.. <i>Journal of Headache and Pain</i> , <b>2022</b> , 23, 41	8.8	4
72	Neurological and Mental Health Symptoms Associated with Post-COVID-19 Disability in a Sample of Patients Discharged from a COVID-19 Ward: A Secondary Analysis.. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19,	4.6	4
71	P070. A 2-year prospective evaluation study on onabotulinumtoxinA 155 U in chronic migraine. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A137	8.8	3
70	Neuroendocrine derangement in chronic migraine. <i>Headache</i> , <b>2006</b> , 46, 1309-10	4.2	3
69	A one-year retrospective economic evaluation of botulinum toxin type A treatment of chronic tension headache. <i>Journal of Headache and Pain</i> , <b>2004</b> , 5, 188-191	8.8	3
68	Reduction in expenditures on analgesics during one year of treatment of chronic tension headache with BoNT-A. <i>Journal of Headache and Pain</i> , <b>2003</b> , 4, 88-91	8.8	3
67	Raised Titers Of Antibodies To Herpes And Epstein-Barr Viruses In Cluster Headache Detected By Emjnofluorescence. <i>Cephalalgia</i> , <b>1987</b> , 7, 351-352	6.1	3
66	Lifting The Burden: The Global Campaign Against Headache <b>2011</b> , 737-744		3
65	Illness Perception and Job Satisfaction in Patients Suffering from Migraine Headaches: Trait Anxiety and Depressive Symptoms as Potential Mediators. <i>Headache</i> , <b>2019</b> , 59, 46-55	4.2	3
64	Coronavirus disease 2019 in patients with cardiovascular disease: clinical features and implications on cardiac biomarkers assessment. <i>Journal of Cardiovascular Medicine</i> , <b>2021</b> , 22, 832-839	1.9	3
63	Zavegepant. Calcitonin gene-related peptide (CGRP) receptor antagonist, Treatment of migraine. <i>Drugs of the Future</i> , <b>2021</b> , 46, 281	2.3	3
62	Epidural steroid-based technique for cervicogenic headache diagnosis. <i>Functional Neurology</i> , <b>1998</b> , 13, 84-7	2.2	3

61	Chronic daily headache and medication overuse headache: clinical read-outs and rehabilitation procedures. <i>Clinica Terapeutica</i> , <b>2007</b> , 158, 343-7		3
60	The Global Campaign turns 18: a brief review of its activities and achievements.. <i>Journal of Headache and Pain</i> , <b>2022</b> , 23, 49	8.8	3
59	Questioning on consistency of a stagnation scale in medication overuse headache: one more added to a plea of emperor's clothes?. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, 13	8.8	2
58	P067. Multimodal therapy in the management of MOH: a 3-year experience. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A135	8.8	2
57	P064. 12 years of Master Degree in Headache Medicine at Sapienza University of Rome. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A187	8.8	2
56	O065. Drug-resistant chronic cluster headache successfully treated with supraorbital plus occipital nerve stimulation. A rare case report. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A97	8.8	2
55	Cytotoxic T lymphocyte antigen 4 polymorphism 49 (A>G) and migraine. <i>Journal of Headache and Pain</i> , <b>2005</b> , 6, 188-90	8.8	2
54	Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study. <i>Pain and Therapy</i> , <b>2021</b> , 10, 1691-1708 <sup>3.6</sup>		2
53	The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer's disease. <i>F1000Research</i> , <b>2020</b> , 9, 1470	3.6	2
52	Multiple Chemical Sensitivity Syndrome: A Principal Component Analysis of Symptoms. <i>International Journal of Environmental Research and Public Health</i> , <b>2020</b> , 17,	4.6	2
51	Eptinezumab for the treatment of migraine. <i>Expert Opinion on Biological Therapy</i> , <b>2021</b> , 21, 999-1011	5.4	2
50	Cluster Headache is Still Lurking in the Shadows. <i>Pain and Therapy</i> , <b>2021</b> , 10, 777-781	3.6	2
49	The effects of the glycaemic control on the severity of the delirium in the advanced phase of Alzheimer's disease. <i>F1000Research</i> , <b>2020</b> , 9, 1470	3.6	2
48	Etiology of 'Sinus Headache'-Moving the Focus from Rhinology to Neurology. A Systematic Review. <i>Brain Sciences</i> , <b>2021</b> , 11,	3.4	2
47	Tele-healthcare in migraine medicine: from diagnosis to monitoring treatment outcomes.. <i>Expert Review of Neurotherapeutics</i> , <b>2022</b> , 1-7	4.3	2
46	Novel Migraine Therapies May Reduce Public and Personal Disadvantages for People with Migraine.. <i>BioDrugs</i> , <b>2022</b> , 1	7.9	2
45	Unmet Needs in Headache Management. <i>Headache</i> , <b>2019</b> , 13-25	0.2	1
44	New Model for Non-Invasive Echocardiographic Assessment of Pulmonary-Capillary Wedge Pressure in Patients With Aortic and Mitral Regurgitation. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 914-918	2.7	1

43	Changing the Approach to Anticoagulant Therapy in Older Patients with Multimorbidity Using a Precision Medicine Approach. <i>International Journal of Environmental Research and Public Health</i> , <b>2018</b> , 15,	4.6	1
42	Framing comorbidities and co-occurrences in a migraine with aura patient. <i>Internal and Emergency Medicine</i> , <b>2014</b> , 9, 603-4	3.7	1
41	Cognition, disability and quality of life of patients with chronic migraine. <i>European Psychiatry</i> , <b>2017</b> , 41, s501-s501	6	1
40	Choosing the safest acute combination therapy during prophylactic treatment: pharmacokinetic and pharmacodynamic considerations. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A36	8.8	1
39	P003. NSAIDs for symptomatic treatment of headache. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A162	8.8	1
38	O068. A 2 years prospective evaluation study on onabotulinumtoxinA 195 U in chronic migraine. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A177	8.8	1
37	Headache and emergency medicine: sharing a language for a common project. <i>Internal and Emergency Medicine</i> , <b>2008</b> , 3 Suppl 1, S1-2	3.7	1
36	Analgesic therapy for headache: consumption, appropriateness and costs. <i>Journal of Headache and Pain</i> , <b>2003</b> , 4, s84-s87	8.8	1
35	Il-2 Induces Pha Proliferation in Peripheral Blood Mononuclear Cells from Cluster Headache Patients. <i>Cephalalgia</i> , <b>1991</b> , 11, 270-271	6.1	1
34	Bioelectrical impedance assay (BIA) of total body composition in alcohol-induced migraine patients. Preliminary report. <i>Headache</i> , <b>1991</b> , 31, 41-5	4.2	1
33	Immune Response Time-Course after Challenge Test in Food-Induced Migraine. <i>Cephalalgia</i> , <b>1989</b> , 9, 164-165	6.1	1
32	Rimegepant for the treatment of migraine. <i>Drugs of Today</i> , <b>2020</b> , 56, 769-780	2.5	1
31	Hormonal therapies in migraine management: current perspectives on patient selection and risk management. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 1-9	4.3	1
30	Access to COVID-19 Vaccination during the Pandemic in the Informal Settlements of Rome.. <i>International Journal of Environmental Research and Public Health</i> , <b>2022</b> , 19,	4.6	1
29	CHA2DS2-VASc score in patients with COVID-19 pneumonia and its relationship with biomarkers of thrombosis, inflammation and myocardial injury. <i>Blood Coagulation and Fibrinolysis</i> , <b>2021</b> ,	1	1
28	Dismantling the Barriers. <i>Headache</i> , <b>2019</b> , 185-201	0.2	1
27	EV435Life satisfaction and enjoyment in medication-overuse headache patients: The role of depression and insomnia. <i>European Psychiatry</i> , <b>2016</b> , 33, S395-S395	6	1
26	Polyamines serum levels in episodic and chronic migraine. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 249-254	4.3	1

25	Fremanezumab. <i>Headache</i> , <b>2021</b> , 131-136	0.2	1
24	New IgM seroconversion and positive RT-PCR test after exposure to the virus in recovered COVID-19 patient <b>2021</b> , 93, 97		1
23	How Does COVID-19 Pandemic Impact on Incidence of Infection and Exacerbation of Its Gastrointestinal Symptoms?. <i>Frontiers in Medicine</i> , <b>2021</b> , 8, 775063	4.9	1
22	O066. Kynurenine pathway metabolites in cluster headache. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A87	8.8	0
21	Thoughts on the past year of Journal of Headache and Pain. <i>Journal of Headache and Pain</i> , <b>2008</b> , 9, 1-2	8.8	0
20	The road ahead for chronic headache patients. <i>Journal of Headache and Pain</i> , <b>2006</b> , 7, 317-9	8.8	0
19	Health status after detoxification in medication overuse headache. <i>Journal of Headache and Pain</i> , <b>2004</b> , 5, 215-216	8.8	0
18	Is There a Gender Difference in the Response to onabotulinumtoxinA in Chronic Migraine? Insights from a Real-Life European Multicenter Study on 2879 Patients. <i>Pain and Therapy</i> , <b>2021</b> , 10, 1605-1618	3.6	0
17	Migraine Outcome Should Not Be Used to Determine Diagnosis, Severity, and Therapy: Moving Towards a Multiparametric Definition of Chronicity.. <i>Pain and Therapy</i> , <b>2022</b> , 1	3.6	0
16	Comparison of Computerized Prescription Support Systems in COVID-19 Patients: INTERCheck and Drug-PIN.. <i>SN Comprehensive Clinical Medicine</i> , <b>2021</b> , 4, 3	2.7	0
15	Chronic Migraine Complicated by Medication Overuse Headache. <i>Headache</i> , <b>2015</b> , 29-34	0.2	
14	Flail Mitral Valve Associated with Iliac Artery Aneurysm: Diagnostic Challenges of a Potential Syndromic Pattern. Case Report. <i>SN Comprehensive Clinical Medicine</i> , <b>2020</b> , 2, 481-484	2.7	
13	"Triaging" Chronic Migraine Patients in Need of CGRP(r) Monoclonal Antibodies. <i>Pain and Therapy</i> , <b>2020</b> , 9, 349-351	3.6	
12	Cytomegalovirus Reactivation in Critically Ill Patient: Cause or Consequence? A Case Report and Literature Review. <i>SN Comprehensive Clinical Medicine</i> , <b>2019</b> , 1, 633-636	2.7	
11	Invasive neurostimulation. <i>Journal of Headache and Pain</i> , <b>2015</b> , 16, A29	8.8	
10	Gleaning after the European Headache Federation consensus statement on refractory chronic migraine. <i>Journal of Headache and Pain</i> , <b>2014</b> , 15, 75	8.8	
9	Reduced IL-2 Receptor Expression on Peripheral Blood Lymphocytes from Cluster Headache Patients. <i>Cephalalgia</i> , <b>1989</b> , 9, 162-163	6.1	
8	Refractory Chronic Migraine: Therapy with Combined Peripheral Neurostimulation. <i>Headache</i> , <b>2015</b> , 75-80	2	

- 7 General Principles of Pharmacotherapy for Headache Disorders. *Headache*, **2016**, 19-29 0.2
- 6 Medical Interventions for Migraine That Has Become Difficult to Treat **2011**, 423-434
- 5 Treatment and Prevention of Migraine **2011**, 255-263
- 4 Prophylactic Drugs. *Headache*, **2020**, 135-151 0.2
- 3 Migraine Versus Cluster Headache and Potential Other Indications. *Headache*, **2021**, 167-172 0.2
- 2 Right Heart Thrombus and Pulmonary Embolism in Patients with Life-Threatening Bleeding: Management of a Complex Condition. *SN Comprehensive Clinical Medicine*, **2021**, 3, 793-795 2.7
- 1 Zavegepant. *Headache*, **2022**, 67-72 0.2